Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00554606 · ClinicalTrials.gov registry record · Phase 2
Long-term Efficacy, Safety and Tolerability of ACZ885 in Patients With Rheumatoid Arthritis
A Phase 2 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 2
- Development phase
- 115
- Enrollment target
NCT00554606 is a Phase 2 study that has completed, run by Novartis. The registered enrollment target is 115 participants.
The verdict
NCT00554606, a Phase 2 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 115 participants
- Enrollment target
Study Summary
This study will assess the long-term safety and tolerability of ACZ885 in patients with rheumatoid arthritis, as well as long-term efficacy, long-term preservation and/or improvement of joint structure and bone mineral density, and long term maintenance of health-related quality of life.
Interventions
- DRUG Canakinumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 115 participants |
| Start Date | 2007-10-11 |
| Est. Completion | 2009-08-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00554606
The ClinicalTrials.gov registry entry for NCT00554606 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 115 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Canakinumab is the first listed.
NCT00554606 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00554606 about?
NCT00554606 is a clinical study titled "Long-term Efficacy, Safety and Tolerability of ACZ885 in Patients With Rheumatoid Arthritis". This study will assess the long-term safety and tolerability of ACZ885 in patients with rheumatoid arthritis, as well as long-term efficacy, long-term preservation and/or improvement of joint structure and bone mineral density, and long term maintenance of health-related quality of life.
What is the current status of trial NCT00554606?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 115 participants. The study started on 2007-10-11. Estimated completion is 2009-08-13.
What interventions are being tested in trial NCT00554606?
The interventions under investigation include: Canakinumab (DRUG).
Who is sponsoring clinical trial NCT00554606?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.